Health Canada Giving Priority Review to Trikafta

Health Canada Giving Priority Review to Trikafta

281869

Health Canada Giving Priority Review to Trikafta

Health Canada is reviewing an application that seeks the approval of Trikafta, a triple combination reported to treat 90% of all with cystic fibrosis (CF), or those with least one F508del mutation. The request from Trikafta’s developer, Vertex Pharmaceuticals, covers eligible patients ages 12 and older, and has been granted priority review. This means a review timeline of 180 days rather than the conventional 300 days; a final decision from Health Canada is expected in the first half…

You must be logged in to read/download the full post.